Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Diamedica Therapeutics Inc (NQ: DMAC )

4.770 +0.070 (+1.49%)
Streaming Delayed Price Updated: 1:51 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Diamedica Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning. 
Via InvestorPlace
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Preview: DiaMedica Therapeutics
Via Benzinga
DiaMedica Therapeutics's Earnings Outlook
Via Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Three (3) Stocks Under $10 That Insiders Are Buying
These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Via Benzinga
DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a  
Via Benzinga
DiaMedica Therapeutics Announces $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday. 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.